Cargando…

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

BACKGROUND: Cerebrospinal fluid biomarker profiles characterized by decreased amyloid-beta peptide levels and increased total and phosphorylated tau levels at threonine 181 (pT181) are currently used to discriminate between Alzheimer’s disease and other neurodegenerative diseases. However, these cha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barthélemy, Nicolas R., Bateman, Randall J., Hirtz, Christophe, Marin, Philippe, Becher, François, Sato, Chihiro, Gabelle, Audrey, Lehmann, Sylvain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079453/ https://www.ncbi.nlm.nih.gov/pubmed/32183883 http://dx.doi.org/10.1186/s13195-020-00596-4

Ejemplares similares

MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology
por: Sato, Chihiro, et al.
Publicado: (2021)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Distinct brain pathologies associated with Alzheimer’s disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-β amyloidosis
por: Hirota, Yu, et al.
Publicado: (2022)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
por: Lehmann, Sylvain, et al.
Publicado: (2020)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry
por: Bros, Pauline, et al.
Publicado: (2015)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer’s Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated
por: Barthélemy, Nicolas R., et al.
Publicado: (2022)

From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid
por: Hirtz, Christophe, et al.
Publicado: (2016)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
por: Marksteiner, Josef, et al.
Publicado: (2022)

New Monoterpenoid Indole Alkaloids from Tabernaemontana crassa Inhibit β-Amyloid42 Production and Phospho-Tau (Thr217)
por: Li, Sheng, et al.
Publicado: (2023)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
por: Tsantzali, Ioanna, et al.
Publicado: (2022)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
por: Yu, Lei, et al.
Publicado: (2023)

Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain
por: Horie, Kanta, et al.
Publicado: (2020)

Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer’s Disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2019)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ(1–42) and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
por: Duron, Emmanuelle, et al.
Publicado: (2018)

Corrigendum: Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aß(1−42), and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
por: Duron, Emmanuelle, et al.
Publicado: (2019)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
por: Wilson, Edward N., et al.
Publicado: (2022)

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study
por: Brickman, Adam M., et al.
Publicado: (2021)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy
por: Dauvilliers, Yves A., et al.
Publicado: (2014)

Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
por: Triana-Baltzer, Gallen, et al.
Publicado: (2020)

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019)

Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
por: De Meyer, Steffi, et al.
Publicado: (2022)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
por: Wennström, Malin, et al.
Publicado: (2022)

Long-Term Depression-Inducing Low Frequency Stimulation Enhances p-Tau181 and p-Tau217 in an Age-Dependent Manner in Live Rats
por: Zhang, Yangyang, et al.
Publicado: (2022)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases
por: Darlix, Amélie, et al.
Publicado: (2019)

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
por: Doré, Vincent, et al.
Publicado: (2022)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9v0mp9s04dhv5cgr5f8q3ikkpp